Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall aim of the proposed project is to improve muscle strength in older adults with possible sarcopenia by promoting home-based progressive resistance exercise. The target population for health talks is community-dwelling older adults. A Three monthly home-visits and weekly phone calls will be made. A waitlist randomised controlled trial will be conducted to evaluate effectiveness, and qualitative feedback will be collected from participants. A pilot study will be conducted first.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | The intervention is a 12-week home-based resistance training programme with phased progression. The intervention will have three phases: (i) an initial phase focused on training the target muscle(s)/movements with minimal or no external weight; (ii) an intermediate phase targeting muscle strength with increased practice resistance; and (iii) an advanced phase targeting the further enhancement of muscle strength by challenging multiple muscle groups. Each phase will involve exercises targeting the trunk, back, hip, upper-limb and lower-limb muscles. |
|
| Waitlist control | Other | The waitlist control participants will start the intervention 12 weeks after the baseline assessment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exercise | Behavioral | The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in lower-limb muscle strength at 12 weeks from baseline | Measured by Short Physical Performance Battery (SPPB), higher score indicates better performance | 12 weeks after baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Change in lower-limb muscle strength at 24 weeks from baseline | Measured by Short Physical Performance Battery (SPPB), higher score indicates better performance | 24 weeks after baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Change in handgrip strength at 12 weeks from baseline | Measured by a spring-type dynamometer, higher value indicates better performance | 12 weeks after baseline |
| Change in handgrip strength at 24 weeks from baseline |
The inclusion criteria are:
The exclusion criteria are:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Community | Hong Kong | Hong Kong |
To protect confidentiality of participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Measured by a spring-type dynamometer, higher value indicates better performance
| 24 weeks after baseline |
| Status of possible sarcopenia at 12 weeks from baseline | Indicated by 5-time chair stand test ≥12 second, or men and women with <28 kg and <18 kg strength | 12 weeks after baseline |
| Status of possible sarcopenia at 24 weeks from baseline | Indicated by 5-time chair stand test ≥12 second, or men and women with <28 kg and <18 kg strength | 24 weeks after baseline |
| Sarcopenia risk score at 12 weeks from baseline | Measured by SARC-CalF, which is a combination of SARC-F questionnaire and calf circumference, a cut of of >=11 indicates high risk | 12 weeks after baseline |
| Sarcopenia risk score at 24weeks from baseline | Measured by SARC-CalF, which is a combination of SARC-F questionnaire and calf circumference, a cut of of >=11 indicates high risk | 24 weeks after baseline |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |